CD44 Rabbit Polyclonal Antibody

CAT#: TA590027

Rabbit Polyclonal CD44 Antibody



 

Need it in bulk or conjugated?
Get a free quote

CNY 5,302.00


货期*
4周

规格
    • 100 ug

Product images

经常一起买 (4)
Transient overexpression lysate of CD44 molecule (Indian blood group) (CD44), transcript variant 1
    • 100 ug

CNY 4,840.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human CD44 molecule (Indian blood group) (CD44), transcript variant 1, 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Recombinant protein of human CD44 molecule (Indian blood group) (CD44), transcript variant 1, 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Applications ELISA
Recommend Dilution WB: 1:5000-1:20000; ELISA: 1:100-1:2000; FC 1:10-1:1000; IHC: 1:10-1:2000; IHC-P 1:250-1:2000
Reactivity Human
Host Rabbit
Clonality Polyclonal
Immunogen DNA immunization. This antibody is specific for the N Terminus Region of the target protein.
Formulation 20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
Concentration 1.01mg/ml
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name CD44 molecule (Indian blood group)
Synonyms CDW44; CSPG8; ECMR-III; HCELL; HUTCH-I; IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1
Note This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT
Reference Data
Protein Families Adult stem cells, Cancer stem cells, Druggable Genome, Embryonic stem cells, ES Cell Differentiation/IPS, Stem cell relevant signaling - DSL/Notch pathway, Transmembrane
Protein Pathways ECM-receptor interaction, Hematopoietic cell lineage
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...